Back to Search
Start Over
Immune mechanism-targeted treatment of experimental epidermolysis bullosa acquisita
- Source :
- Expert review of clinical immunology. 11(12)
- Publication Year :
- 2015
-
Abstract
- Epidermolysis bullosa acquisita (EBA) is an autoimmune bullous dermatosis characterized by chronic mucocutaneous blistering caused by autoantibodies directed against type VII collagen. EBA causes a high morbidity and is difficult to treat. Model systems have significantly broadened our understanding of EBA pathogenesis, leading to the identification of numerous therapeutic targets. Of these, so far, a few have been evaluated for their therapeutic potential in preclinical models. In mice, EBA can be induced by transfer of anti-type VII collagen antibodies or by immunization with the protein. The latter model, immunization-induced EBA, is ideal to test drugs for their therapeutic efficacy. Here, mice with already established disease can be treated for prolonged periods. Albeit time consuming, results from immunization-induced EBA will pave the way for clinical application in patients. As the key pathogenic principle, that is, autoantibody-induced, leukocyte-mediated tissue injury and inflammation, is shared by other diseases, these findings may have translational applications beyond EBA.
- Subjects :
- Epidermolysis bullosa acquisita
Collagen Type IV
Anakinra
business.industry
Immunology
Mucocutaneous zone
Autoantibody
Inflammation
Disease
Epidermolysis Bullosa Acquisita
medicine.disease
Pathogenesis
Disease Models, Animal
Mice
Immune system
parasitic diseases
medicine
Immunology and Allergy
Animals
Humans
medicine.symptom
business
medicine.drug
Autoantibodies
Subjects
Details
- ISSN :
- 17448409
- Volume :
- 11
- Issue :
- 12
- Database :
- OpenAIRE
- Journal :
- Expert review of clinical immunology
- Accession number :
- edsair.doi.dedup.....de077beed8c20a183793e78f162c8cd4